Last reviewed · How we verify
Chronic kidney disease at increased risk of cardiovascular disease — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Inpefa | SOTAGLIFLOZIN | Lexicon Pharms Inc | Sodium-Glucose Cotransporter 2 Inhibitor [EPC] | Sodium/glucose cotransporter 2 | 2023-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Lexicon Pharms Inc · 1 drug in Chronic kidney disease at increased risk of cardiovascular disease
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Chronic kidney disease at increased risk of cardiovascular disease:
- Chronic kidney disease at increased risk of cardiovascular disease treatment updates — RSS
- Chronic kidney disease at increased risk of cardiovascular disease treatment updates — Atom
- Chronic kidney disease at increased risk of cardiovascular disease treatment updates — JSON
Cite this brief
Drug Landscape (2026). Chronic kidney disease at increased risk of cardiovascular disease — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/chronic-kidney-disease-at-increased-risk-of-cardiovascular-disease. Accessed 2026-06-10.
Related
- Chronic kidney disease at increased risk of cardiovascular disease full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing